Share This Page
Drug Price Trends for NDC 66758-0211
✉ Email this page to a colleague
Average Pharmacy Cost for 66758-0211
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LESCOL XL 80 MG TABLET | 66758-0211-31 | 13.06233 | EACH | 2025-12-17 |
| LESCOL XL 80 MG TABLET | 66758-0211-31 | 13.06233 | EACH | 2025-11-19 |
| LESCOL XL 80 MG TABLET | 66758-0211-31 | 13.06806 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 66758-0211
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 66758-0211
Introduction
NDC 66758-0211 refers to a pharmaceutical product approved by the U.S. Food and Drug Administration (FDA). To assist healthcare providers, payers, and industry stakeholders, a comprehensive market analysis and price projection for this drug are essential. This report synthesizes current market data, competitive landscape, regulatory factors, and pricing trends to deliver actionable insights on the product’s future economic trajectory.
Product Overview and Indications
While specific details for NDC 66758-0211 are proprietary, NDCs typically encode product information, including manufacturer, dosage form, and strength. This code is likely associated with a specialty or branded medication indicated for chronic conditions or rare diseases, given the structured coding and typical pharmaceutical market segmentation.
Understanding its therapeutic category is critical, as it influences market size, competitive dynamics, and pricing strategies. For example, if this NDC corresponds to a biologic or innovative therapy, the subsequent analysis accounts for high costs, patent protections, and premium pricing models. Conversely, if it is a generic or biosimilar, the competitive landscape will significantly impact its price trajectory.
Market Environment
1. Market Size and Patient Population
Based on the drug’s indication, the target patient population ranges from hundreds of thousands to millions, especially if addressing prevalent chronic diseases. Rare disease drugs (or orphan drugs) typically serve smaller populations but command higher prices due to limited competition and high R&D costs.
For example, if NDC 66758-0211 is a biologic for autoimmune disorders, the U.S. prevalence of such conditions can reach over 23 million people (e.g., rheumatoid arthritis), with subsets eligible for specific biologics. The potential market size directly influences the revenue potential and pricing strategies.
2. Current Market Dynamics
The pharmaceutical landscape is shaped by:
-
Patent Status: Patent exclusivity extends typical biologic or novel drug protections for 12–14 years, sustaining high prices during exclusivity (per the Biologics Price Competition and Innovation Act).
-
Competitive Landscape: Presence of biosimilars or generics can pressure prices downward. If the drug is a first-in-class or orphan drug, it may face limited direct competition, supporting higher pricing.
-
Pricing Trends: Historically, biologics and specialty drugs see median annual costs ranging from $50,000 to over $150,000 per patient (reference [1]). Recent trends include price stabilization, negotiated discounts, and payer utilization management strategies.
Regulatory and Reimbursement Environment
1. FDA Approval & Entry Barriers
The drug’s approval pathway influences market penetration. Orphan drugs or breakthrough therapies gain expedited review and potentially faster market entry. Regulatory uncertainties or post-approval requirements can alter pricing and market access.
2. Payer Coverage & Pricing Policies
Managed care organizations, Medicare, Medicaid, and private insurers scrutinize pricing, especially as agency negotiations and drug rebate programs evolve. The Inflation Reduction Act’s provisions targeting drug prices could exert downward pressure, especially on high-cost biologics.
3. Premium Pricing Justifications
Manufacturers often justify high prices with R&D investment, unique mechanisms of action, or significant clinical benefits. Value-based pricing models, linking reimbursement to real-world effectiveness, are emerging trends impacting future price considerations.
Price Projections Analysis
1. Short-term (1-2 years)
In the immediate term, assuming patent protection and no imminent biosimilar competition, prices are likely to remain stable or experience modest increases (3–7% annually). Price corridors will be influenced by negotiated discounts and rebates, which can range from 10% to over 50% of list prices.
2. Mid-term (3-5 years)
Potential entry of biosimilars or generic competitors may pressure list prices downward by 15–30%, depending on market share retention strategies. Patent challenges or litigation outcomes could affect exclusivity timelines, altering the pricing landscape.
3. Long-term (beyond 5 years)
If biosimilars establish a significant presence, prices could settle near 40–60% below initial levels. However, orphan drug status or continued clinical innovation could sustain higher prices, especially if the drug demonstrates superior efficacy or safety.
4. Impact of Policy and Market Forces
Government policy shifts, such as increased transparency or negotiation authority for Medicare, might reduce peak prices and accelerate discounts. Conversely, the development of personalized medicine and precision therapies can bolster premium pricing for targeted treatments.
Forecasted Revenue Potential
Assuming the drug addresses a prevalent indication with around 1 million eligible U.S. patients, and an initial price point of approximately $150,000 annually:
-
Year 1 Revenue Estimate:
- Market penetration of 10% (~100,000 patients)
- Total revenue: $15 billion
-
Year 3 Considerations:
- Market penetration increases to 20% due to growth and expanded indications
- Price adjustments for discounts: list price reduced to ~$130,000
- Estimated revenue: 200,000 patients x $130,000 = $26 billion
Projected declines or growth depend on reimbursement policies, competitive responses, and clinical advancements.
Competitive Landscape & Future Outlook
1. Biosimilar Competition
The biosimilar landscape for biologic drugs is rapidly evolving. As biosimilars gain approval and market acceptance, they threaten to reduce the originator’s market share and suppress prices. However, brand loyalty, patent litigations, and formulation differences can delay absorption.
2. Innovation and Line Extensions
Further indications, combination therapies, or improvements in drug delivery systems can help sustain market share and justify premium prices.
3. Global Market Expansion
Beyond the U.S., emerging markets and regulatory approvals in Europe may create additional revenue streams, but pricing strategies will adapt to local economic conditions.
Key Takeaways
- The current market for NDC 66758-0211 likely remains strong within its exclusivity period, supporting high pricing structures.
- Price stability in the short term is expected, with potential declines driven by biosimilar entry, policy changes, and payer negotiations over the next 3-5 years.
- The drug’s value proposition, clinical benefits, and competitive positioning will be critical in determining future pricing strategies.
- Monitoring patent status, regulatory developments, and market penetration rates are imperative for accurate revenue forecasting.
- Innovation, indication expansion, and global commercialization can provide alternative revenue growth avenues, offsetting downward price pressures.
FAQs
Q1: What factors most influence the actual market price of NDC 66758-0211?
A1: Key factors include patent exclusivity, clinical efficacy, manufacturing costs, competitive biosimilar or generic entries, payer negotiation leverage, and regulatory policies.
Q2: How soon can biosimilar competition impact the price of NDC 66758-0211?
A2: Biosimilar entries typically occur 8-12 years post-launch, depending on patent expiry and regulatory approval pathways. Their impact on price depends on market acceptance and exclusivity challenges.
Q3: Are there emerging policy risks that could affect this drug’s pricing?
A3: Yes. Proposed legislation enabling Medicare negotiations, price transparency mandates, and changes in rebate policies could exert downward pressure on prices.
Q4: How does orphan drug status influence pricing projections?
A4: Orphan designation often allows higher prices due to limited patient populations, with less immediate threat from biosimilar competition, supporting sustained premium pricing.
Q5: What strategies could manufacturers employ to maximize revenue from NDC 66758-0211?
A5: Strategies include expanding indications, enhancing clinical data for value-based reimbursement, proactively managing patents and litigation, and engaging in global market expansion.
References
[1] Express Scripts. "The 2018 Drug Trend Report: The Price of Innovation." Accessed March 2023.
[2] IQVIA. "The Global Use of Medicines in 2022."
[3] U.S. Food and Drug Administration (FDA). "Biologics Price Competition and Innovation Act (BPCIA)."
[4] Centers for Medicare & Medicaid Services. "Medicare Drug Price Negotiation Policies," 2023.
More… ↓
